BACKGROUND: Reconstruction of the breast after mastectomy is an integral part of the complete management of breast cancer. However, a delay in the reconstruction is usually proposed after the mastectomy in case of invasive cancer, while there is a general agreement for immediate breast reconstruction in case of in situ tumors. PATIENTS AND METHODS: Among a total of 677 patients having undergone a mastectomy between 1997 and 2001, 518 (76.5%) underwent an immediate breast reconstruction (IBR). All the patients had a Patey mastectomy for invasive cancer (T1-T3). An adjuvant medical treatment was given according to the biological characteristics of the tumor and lymph node status. No patient received any kind of radiotherapy. The median follow up was 70 months (range 13-114). RESULTS: The local recurrence rate was 5.2% for the group of IBR and 9.4% for the mastectomy group without IBR (NoIBR). The regional metastases rate was 1.4 vs. 1.3%. The rate of distant metastases was 13.9 vs. 16.4%. Contra-lateral breast tumor was observed in 1.5 vs. 1.3%. Death rate was 10.4 vs. 16.4%. No statistical difference was observed between the two groups in terme of overall survival (OS) and disease free survival (DFS) (HR(IBR vs. NoIBR): 1.03 and 0.99 for OS and DFS, respectively). CONCLUSION: At our institution we have compared a large series that have undergone IBR (518) with a control group (159) and followed over a prolonged period of time (70 months). This study provides the best available results to suggest that IBR is a safe and reliable treatment option for the managing invasive breast cancer.
BACKGROUND: Reconstruction of the breast after mastectomy is an integral part of the complete management of breast cancer. However, a delay in the reconstruction is usually proposed after the mastectomy in case of invasive cancer, while there is a general agreement for immediate breast reconstruction in case of in situ tumors. PATIENTS AND METHODS: Among a total of 677 patients having undergone a mastectomy between 1997 and 2001, 518 (76.5%) underwent an immediate breast reconstruction (IBR). All the patients had a Patey mastectomy for invasive cancer (T1-T3). An adjuvant medical treatment was given according to the biological characteristics of the tumor and lymph node status. No patient received any kind of radiotherapy. The median follow up was 70 months (range 13-114). RESULTS: The local recurrence rate was 5.2% for the group of IBR and 9.4% for the mastectomy group without IBR (NoIBR). The regional metastases rate was 1.4 vs. 1.3%. The rate of distant metastases was 13.9 vs. 16.4%. Contra-lateral breast tumor was observed in 1.5 vs. 1.3%. Death rate was 10.4 vs. 16.4%. No statistical difference was observed between the two groups in terme of overall survival (OS) and disease free survival (DFS) (HR(IBR vs. NoIBR): 1.03 and 0.99 for OS and DFS, respectively). CONCLUSION: At our institution we have compared a large series that have undergone IBR (518) with a control group (159) and followed over a prolonged period of time (70 months). This study provides the best available results to suggest that IBR is a safe and reliable treatment option for the managing invasive breast cancer.
Authors: D L Hershman; C A Richards; K Kalinsky; E T Wilde; Y S Lu; J A Ascherman; A I Neugut; J D Wright Journal: Breast Cancer Res Treat Date: 2012-09-29 Impact factor: 4.872
Authors: Yue-Yung Hu; Christine M Weeks; Haejin In; Christopher M Dodgion; Mehra Golshan; Yoon S Chun; Michael J Hassett; Katherine A Corso; Xiangmei Gu; Stuart R Lipsitz; Caprice C Greenberg Journal: Cancer Date: 2011-01-24 Impact factor: 6.860
Authors: Terence M Myckatyn; I Janelle Wagner; Babak J Mehrara; Melissa A Crosby; Julie E Park; Bahjat F Qaqish; Dominic T Moore; Evan L Busch; Amanda K Silva; Surinder Kaur; David W Ollila; Clara N Lee Journal: Plast Reconstr Surg Date: 2017-01 Impact factor: 4.730
Authors: Julie E Lang; Danielle E Summers; Haiyan Cui; Joseph N Carey; Rebecca K Viscusi; Craig A Hurst; Amy L Waer; Michele L B Ley; Stephen F Sener; Aparna Vijayasekaran Journal: J Surg Oncol Date: 2013-07-16 Impact factor: 3.454
Authors: Young Woo Chang; Hwan Soo Kim; Seung Pil Jung; Sang Uk Woo; Jae Bok Lee; Jeoung Won Bae; Gil Soo Son Journal: World J Surg Oncol Date: 2017-07-14 Impact factor: 2.754